1
|
Scibona P, Burgos Pratx LD, Savoy N, Recart D, Elia Y, Seoane FN, Arrigo D, Portalis MR, Roldan A, Cassoratti BA, Diaz JC, Antonelli CE, Perez L, Posadas-Martinez L, Belloso WH, Simonovich V. Long-term antibody titers variation in unvaccinated patients receiving convalescent plasma or placebo for severe SARS-CoV-2 pulmonary infection. Transfus Apher Sci 2023; 62:103785. [PMID: 37620184 DOI: 10.1016/j.transci.2023.103785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 08/10/2023] [Accepted: 08/11/2023] [Indexed: 08/26/2023]
Abstract
BACKGROUND Convalescent plasma (CP) became a prominent treatment in the early stages of the SARS-CoV-2 pandemic. In Argentina, a randomized clinical trial was executed to compare the use of CP in inpatients with severe COVID-19 pneumonia versus placebo. No differences in clinical outcomes or overall mortality between groups were observed. We conducted a cohort study in outpatients enrolled in the trial to describe long-term antibody titer variations between CP and placebo recipients. METHODS Patients' total SARS-CoV-2 IgG antibodies against spike protein were collected 3, 6 and 12 months after hospital discharge from August 2020 to December 2021. In addition, reinfections, deaths and vaccination status were retrieved. Statistical analysis was performed using antibody geometric mean titers (GMT). All estimations were made considering the date of the trial infusion (placebo or CP) as time 0. RESULTS From the 93 patients included in the follow-up, 64 had received CP and 29 placebo. We excluded all 12-month measurements because they were collected after the patients' vaccination date. At 90 days post-infusion, patients had an antibody GMT of 8.1 (IQR 7.4-8.1) in the CP group and 8.8 (IQR 8.1-9.1) in the placebo group. At 180 days, both groups had a GMT of 8.1 (IQR 7.4-8.1). No statistical differences in GMT were found between CP and placebo groups at 90 days (p = 0.12) and 180 days (p = 0.25). No patients registered a new COVID-19 infection; one died in the CP group from an ischemic stroke. CONCLUSIONS No differences were observed in long-term antibody titers in unvaccinated patients that received CP or placebo after severe COVID-19 pneumonia.
Collapse
Affiliation(s)
- Paula Scibona
- Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| | - Leandro Daniel Burgos Pratx
- Transfusional Medicine Department, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199 Buenos Aires, Argentina
| | - Nadia Savoy
- Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| | - Delfina Recart
- Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina.
| | - Yasmin Elia
- Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| | - Facundo Nahuel Seoane
- Virology Section, Central Laboratory, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| | - Diego Arrigo
- Virology Section, Central Laboratory, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| | - Maximo Rousseau Portalis
- Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, C1121A6B Buenos Aires, Argentina
| | - Agustina Roldan
- Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, C1121A6B Buenos Aires, Argentina
| | | | - Julio Cesar Diaz
- Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, C1121A6B Buenos Aires, Argentina
| | | | - Lucia Perez
- Department of Research, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199 Buenos Aires, Argentina
| | - Lourdes Posadas-Martinez
- Department of Research, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199 Buenos Aires, Argentina
| | - Waldo H Belloso
- Terra Nova Innovation Unit, Hospital Italiano de Buenos Aires, Argentina
| | - Ventura Simonovich
- Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina
| |
Collapse
|